TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Prescient Therapeutics Limited ( (AU:PTX) ) has issued an update.
Prescient Therapeutics Limited announced a change in the director’s interest, with James Campbell acquiring 5,257,573 unlisted options exercisable at $0.10, expiring on 17 November 2029. This change was approved by shareholders at the company’s Annual General Meeting, indicating strategic alignment and potential growth opportunities for the company.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on the development of innovative cancer therapies. The company is engaged in advancing targeted and personalized medicine approaches to improve treatment outcomes for cancer patients.
Average Trading Volume: 934,319
Technical Sentiment Signal: Hold
Current Market Cap: A$60.99M
For detailed information about PTX stock, go to TipRanks’ Stock Analysis page.